Brief: Docmorris H1 EBITDA At CHF -20.8 Mln

DocMorris AG

17/08/2023 06:10

Aug 17 (Reuters) - DOCMORRIS AG  DOCM.S :
    * DOCMORRIS: SOLID BASIS FOR SUSTAINABLE, PROFITABLE GROWTH
    * REVENUE AND EARNINGS WITHIN FULL-YEAR GUIDANCE RANGE
    * GROWTH TREND REVERSAL IN Q2 OF 2023
    * CONSISTENT FOCUS ON PROFITABILITY: EBITDA (ADJUSTED)
IMPROVED BY
CHF 33.9 MILLION
    * E-PRESCRIPTION ROLLOUT ACCELERATES SIGNIFICANTLY
    * SALE OF SWISS BUSINESS SIGNIFICANTLY STRENGTHENS BALANCE
SHEET:
EQUITY RATIO RISES TO CLOSE TO 50%
    * MANAGEMENT CONFIRMS ITS 2023 TARGETS COMMUNICATED IN MARCH
    * GROSS MARGIN INCREASED BY 5.5 PERCENTAGE POINTS TO 21.6
PER CENT
IN FIRST HALF OF YEAR COMPARED TO SAME PERIOD LAST YEAR
    * MID-TERM, AN ADJUSTED EBITDA MARGIN OF 8 PER CENT
CONTINUES TO
BE TARGETED
    * EXPECTS TO BREAK-EVEN ON ADJUSTED EBITDA IN 2024,
EXCLUDING
E-PRESCRIPTIONS
    * IN GROUP CURRENCY, EXTERNAL REVENUE 1  WAS CHF 252.7
MILLION IN
Q2 AND CHF 501.4 MILLION IN FIRST HALF.
    * EQUITY RATIO INCREASED SIGNIFICANTLY FROM 31.9 PER CENT AS
OF 31
DECEMBER 2022 TO 48.9 PER CENT AS OF 30 JUNE 2023

Source text for Eikon:  ID:nEQ7GLYx5a 
Further company coverage:  DOCM.S 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))